Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin-D Braces For Winter With Common Cold New Use Claim

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough could leverage its new common cold usage claim for Claritin-D 12- and 24-Hour tablets as the company shifts its focus for the brand from the spring allergy season to the fall cough/cold season

You may also be interested in...



Claritin Growth Plateaus As Schering Moves Ahead With Consent Decree

Sales of Schering-Plough's Claritin (loratadine) appear to have leveled off following a strong 2003 campaign for the over-the-counter antihistamine

Claritin Growth Plateaus As Schering Moves Ahead With Consent Decree

Sales of Schering-Plough's Claritin (loratadine) appear to have leveled off following a strong 2003 campaign for the over-the-counter antihistamine

Sales & Earnings In Brief

Schering-Plough: Double-digit gains by OTC Claritin and sun care triggered a strong second quarter for the consumer health division, up 19% to $317 mil. Claritin sales jumped 22% to $117 mil. due to trade inventory adjustments in the year-ago quarter. Sun care revenue totaled $78 mil. (up 60%) as a result of the "timing of orders and shipments, coupled with favorable weather conditions," and foot care rose 7% to $89 mil. Schering has "good work underway" on new Coppertone and Dr. Scholl's extensions, CEO Fred Hassan tells analysts July 21. The solid consumer health results were more than offset by continuing struggles in Rx pharmaceuticals, spending on the FDA consent decree and restructuring costs. Consolidated sales fell 7% to $2.15 bil. and the firm reported a net loss of $65 mil...

Related Content

Topics

UsernamePublicRestriction

Register

PS097138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel